Globus Medical ( (GMED) ) has released its Q3 earnings. Here is a breakdown of the information Globus Medical presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Globus Medical, Inc. is a prominent global company specializing in musculoskeletal solutions, focusing on spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. The company is dedicated to addressing unmet clinical needs and advancing patient care through innovation and education.
In its third-quarter earnings report for 2025, Globus Medical announced a significant increase in worldwide net sales, reaching $769 million, marking a 22.9% rise compared to the same period in the previous year. The company’s U.S. sales saw a notable 24.6% increase, while international sales grew by 16.5%. The recent acquisition of Nevro has been a key contributor to this growth, exceeding expectations and demonstrating the success of Globus Medical’s integration strategy.
Key financial highlights include a GAAP net income of $119 million, a 129.5% increase from the prior year, and a GAAP diluted earnings per share of $0.88. The non-GAAP diluted EPS rose by 42.6% to $1.18. The company also achieved a record non-GAAP free cash flow of $213.9 million, a 24% increase from the previous quarter. Additionally, Globus Medical executed $40 million in share repurchases, reflecting confidence in its business and commitment to shareholder value.
The company’s strategic focus on operational efficiency and synergy execution has resulted in enhanced earnings and profitability, with improvements in adjusted gross margins and operating expenses. The Nevro acquisition has been particularly beneficial, contributing $99.3 million to the sales increase. Globus Medical has raised its full-year 2025 revenue guidance to a range of $2.86 to $2.90 billion, with expectations for the Nevro acquisition to be accretive to earnings.
Looking ahead, Globus Medical remains committed to driving consistent organic growth through innovation and disciplined execution. The company aims to deliver differentiated technologies that improve patient outcomes, positioning itself for continued success in the musculoskeletal solutions market.